Spermosens (SPERM.ST) Stock Analysis & AI Equity Report
Spermosens (SPERM.ST) overview
Spermosens (SPERM.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Spermosens reported revenue of SEK 0m and operating profit of SEK -9.2m; the year-end share price was 0.01 SEK and market capitalisation was SEK 14.7m. Spermosens is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Spermosens's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Spermosens
Spermosens AB develops diagnostic medical devices for male infertility and assisted reproduction. Its main product, JUNO-Checked, is designed to measure sperm binding capacity to help assess fertility potential and guide IVF treatment decisions. The company focuses on clinical validation, intellectual property, and commercial partnerships as it works toward licensing its technology to laboratories and fertility providers.
Generate the Spermosens report
Spermosens is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Spermosens and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.